Arena Pharma (ARNA) Reports Complete Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis; Provides Program Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. CCH:LN
5. META
6. CCHGY
7. PRY:IM
8. PRYMY
9. SKA-B
10. PBA

Go back to Arena Pharma (ARNA) Reports Complete Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis; Provides Program Updates

Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates

May 26, 2020 8:30 AM EDT

SAN DIEGO, May 26, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 2b ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe atopic dermatitis. The trial enrolled 140 patients at study sites across the United States, Canada... More